Hepatitis Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatitis B Virus Therapy
Reports from Center for Virology, Department of Infection describe recent advances in hepatitis B virus therapy
August 6th, 2007
Investigators publish new data in the report "Presence of hepatitis B virus core promoter mutations pre-seroconversion predict persistent viral replication after HBeAg loss. In patients with chronic hepatitis B virus (HBV) infection DNA levels do not always fall after anti-hepatitis B e (anti-HBe) seroconversion. To follow longitudinally through HB e antigen (HBeAg) loss HBV DNA levels and core promoter/precore sequences in a cohort of 21 chronic HBV carriers. Treatment-naïve HBeAg seropositive HBV carriers were monitored through HBeAg loss for between 2 and 22 years (mean 9.3). Core promoter/precore sequences, genotypes, HBV DNA levels and HBe status were determined," investigators in...
Source: Hepatitis Weekly (2007-08-06)
|
